VivoSeq
Other

Ph+ ALL

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Ph+ ALL is an early-stage landscape with 0 programs across 2 companies. The most active players are Novartis, Otsuka.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalOtsuka logo

Otsuka

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Active, not recruiting2 · 50%
Unknown status1 · 25%
Completed1 · 25%

Clinical Trials

Trial Activity

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
Active, not recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT04475731·67 enrolled
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03624530·82 enrolled
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Completed·Novartis logoNovartis·Phase 1·NCT02081378·326 enrolled
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Active, not recruiting·Otsuka logoOtsuka·Phase 2·NCT04233346·93 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)